Check out our latest podcast episode: CUTTING EDGE ADVANCES IN THE TREATMENT OF LUNG CANCER with Dr. Barbara Melosky: https://t.co/weDULeNNgC.

In honour of Earth Day, we wanted to share our new webpage dedicated to sustainability: https://t.co/gD1EVKmwdM. At IMPACT Medicom, we take pride in our efforts towards sustainability, with a commitment to plant 50 trees per project sold. We have now planted over 1,000 trees!

Check out our latest podcast episode: BIOMARKERS IN UPPER GI CANCER with @DrCBrezden and Dr. Catherine Streutker: https://t.co/9vnm5OS2ff.

Our latest podcast episode is up: Immunotherapy for Kidney Transplant Patients with Skin Cancer with Dr. Evan Lipson: https://t.co/vtYYXMtQdN. Follow our podcast on Spotify at https://t.co/59GC9woMPG.

Check out our latest video capsule where Dr. Mark Taylor discusses the surgical implications for the treatment of cutaneous Squamous Cell Carcinoma. https://t.co/dsuumJpq3E. #skincancer #surgeon

Check out our latest video capsule where @evanlipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant: https://t.co/NipZVr3waS.

Updates from ASH 2023: Check out our congress summary on the latest updates in CLL. With @LymphomaDocDave and @v_banerji : https://t.co/vJOj2abonh.

Check out our latest video capsule from @ASH_hematology ASH 2023 - A Perspective on CLL with @v_banerji and @LymphomaDocDave: https://t.co/S1rXtSejQn

Live from ASH: Our latest video capsule includes Dr. Rami Kotb @MyelomaCanada and @CancerCareMB and Dr. Donna Reece @pmcancercentre and @UofT discussing their study on Isa-CYBORD in RR Transplant Eligible MM. https://t.co/MYc89Zd2En. #multiplemyeloma

LIVE FROM @ASH_hematology, Dr. Jennifer Brown from @DanaFarberNews discusses updates to the ALPINE trial on zanubrutinib vs ibrutinib in CLL: https://t.co/6QR4xWbrIm

At the @ASH_hematology meeting in San Diego. Exciting atmosphere, love these opportunities to learn about promising new treatments.

Du nouveau d'importance dans le cancer urothélial avancé! Des résultats dont le @chumontreal peut être fier d'avoir contribué.

Live from ESMO!! Check out our video capsule on first-line treatment strategies for the management of la/mUC with Dr. Thomas Powles @tompowles1 and a Canadian discussion with @NormandBlais , Dr. Srikala Sridhar, and Dr Bernie Eigle: https://t.co/gHesttJVdy.  #bladdercancer

♨️ - EV302. Simply amazing: OS was significantly prolonged with EV+P vs chemo, reducing the risk of death by 53% (median OS, 31.5 mo vs 16.1 mo, respectively). Can’t wait to witness this breakthrough live #ESMO23

We are celebrating 8 years in business with a new and improved website: https://t.co/r70roFxgpp. Come and check it out!

🔥off the press: ESMO Guidance for Reporting Oncology real-World evidence (GROW) @Annals_Oncology https://t.co/f81jxXmRZc 👉RWD are gaining increasing interest to complement clinical trials 👉Here, we provide detailed recommendations for reporting RWE studies in oncology @myESMO

Our final podcast episode r on "First Line la/mUC Evolving Treatment Strategies" is up. This episode with @NormandBlais Dr. Srikala Sridhar, and Dr Terence Friedlander features a round table discussion on the treatment of 1L la/mUC.  https://t.co/LNgkB8fheS.  #bladdercancer

Our final video capsule of the Webinar on "First Line la/mUC Evolving Treatment Strategies" is up. With @NormandBlais , Dr. Srikala Sridhar, and Dr Terence Friedlander and features a round table discussion on the treatment of 1L la/mUC. https://t.co/OwdbuYjuZI. #bladdercancer

More (impressive) data on the intracranial activity of T-DXd. Real-world cohort from Japan, including 104 patients with HER2+ MBC, of which 90 with active brain mets and 19 with LMD. Consistently with TUXEDO-1, IC-ORR was 63%, IC-PFS was 16 months. #bcsm https://t.co/lcjU2GNUDt

@NormandBlais